Powder Or Dust Containing Patents (Class 424/46)
  • Patent number: 7914770
    Abstract: An improved suspension formulation for use in a metered-dose inhaler having a hydro-fluoro-alkane propellant is described, the improvement being the controlled addition of a small quantity of water.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: March 29, 2011
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: George DeStefano, Linda Jean Kelash-Cannavo
  • Patent number: 7892781
    Abstract: A test agent includes a composite probe having at least one nanoparticle having multiple metal atoms, a directing agent, and an enzyme. The directing agent attaches the probe to a target in a test sample. The test sample and bound probe are then treated with an enzyme substrate. A method of detecting a target in a test sample includes exposing the test sample to the probe, then treating the test sample with an enhancement or development solution to deposit at least one of a fluorophore, a chromogen, or a metal.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: February 22, 2011
    Assignee: Nanoprobes, Inc.
    Inventors: Richard D. Powell, Vishwas N. Joshi, James F. Hainfeld
  • Publication number: 20110038807
    Abstract: The present invention is directed to a method for treating bipolar disorder, childhood-onset bipolar disorder, and associated symptoms. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder and childhood-onset bipolar disorder.
    Type: Application
    Filed: August 14, 2009
    Publication date: February 17, 2011
    Inventor: Demitri Papolos
  • Publication number: 20110027193
    Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).
    Type: Application
    Filed: October 12, 2010
    Publication date: February 3, 2011
    Applicant: Lasser Family Partnership, L.P.
    Inventors: Elliott C. Lasser, Kenneth H. Lasser
  • Patent number: 7879358
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: February 1, 2011
    Assignee: Alkermes, Inc.
    Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20100329984
    Abstract: A respiratory dispersion for pulmonary delivery comprises one or more bioactive agents, a suspension medium, and a plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 ?m. The suspension medium comprises at least one propellant and permeates the perforated microstructures.
    Type: Application
    Filed: September 3, 2010
    Publication date: December 30, 2010
    Applicant: NOVARTIS AG
    Inventors: Jeffry G. WEERS, Ernest G. SCHUTT, Luis A. DELLAMARY, Thomas E. TARARA, Alexey KABALNOV
  • Publication number: 20100329999
    Abstract: According to a first aspect, antiperspirant aerosol compositions are disclosed comprising antiperspirant active particulates, a propellant and at least 5% by weight of the entire antiperspirant aerosol composition of a silicone component, wherein (a) the antiperspirant active particulates are the only particulates in the antiperspirant aerosol composition; (b) the silicone component comprises one or more silicones and the or each silicone is a non-volatile silicone. According to a second aspect, packaged antiperspirant aerosol compositions according to the first aspect are disclosed.
    Type: Application
    Filed: September 10, 2010
    Publication date: December 30, 2010
    Inventor: Scott Edward SMITH
  • Publication number: 20100330186
    Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein X? is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.
    Type: Application
    Filed: September 3, 2010
    Publication date: December 30, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Christopher John Montague MEADE, Michel PAIRET, Michael P. PIEPER
  • Patent number: 7846462
    Abstract: Skin care or cleansing implements are described containing a liquid, semi-solid or solid cleansing or skin treatment composition that is releasably associated with the implement. The composition is substantially nonaqueous and has a continuous and a discontinuous phase. Components of the discontinuous phase can react with each other or with water when water is blended with the nonaqueous cleansing or skin treatment composition during consumer use. Methods for treating the skin with the inventive implements are also described.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: December 7, 2010
    Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.
    Inventors: Alessandro Luigi Spadini, Melissa Iva Katz, David Robert Williams, Marcina Siciliano, Gregory Aaron Grissett, Evan Hillman, Andre Puleo, Megan Kathleen Hurley
  • Patent number: 7842284
    Abstract: A regimen for hunting includes using a number of zeolite-containing personal items in connection with a hunter's apparel and body to reduce the hunter's scent for improved hunting. The personal items include mouthwash, deodorant/anti-perspirant, body and boot powder, bar and liquid soap for cleansing the body and hair, laundry detergent and dryer sheets. Each of the personal items includes an effective amount of zeolite, so that use of the personal items reduces the available scent to be detected by animals in the wild. The regimen can also include the use of a seat cushion that is covered with an activated carbon-containing fabric for odor control and/or elimination.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: November 30, 2010
    Assignee: Johnson Laboratories, Inc.
    Inventor: Louis B. Johnson
  • Publication number: 20100284940
    Abstract: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.
    Type: Application
    Filed: July 19, 2010
    Publication date: November 11, 2010
    Applicant: MAP Pharmaceuticals, Inc.
    Inventors: Robert O. COOK, Stephen B. Shrewsbury, Nabih N. Ramadan, Thomas A. Armer
  • Publication number: 20100285142
    Abstract: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.
    Type: Application
    Filed: May 18, 2010
    Publication date: November 11, 2010
    Applicant: Vectura Limited
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rossella Musa
  • Patent number: 7807200
    Abstract: Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: October 5, 2010
    Assignee: Alkermes, Inc.
    Inventors: Michael M. Lipp, Richard P. Batycky, Giovanni Caponetti
  • Publication number: 20100247452
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: EPOPLUS GMBH & CO. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller
  • Publication number: 20100247450
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: EPOPLUS GMBH & CO. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller
  • Publication number: 20100247451
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: EPOPLUS GMBH & CO. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller
  • Patent number: 7790145
    Abstract: A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: September 7, 2010
    Assignee: Novartis AG
    Inventors: Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
  • Publication number: 20100215590
    Abstract: The invention relates to a method for producing a micronized, virtually anhydrous form of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide, said form per se, and the use thereof for producing a medicament, especially a medicament having an anticholinergic effect.
    Type: Application
    Filed: December 7, 2006
    Publication date: August 26, 2010
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Norbert Rasenack, Mihael Walz, Michael Trunk, Hagen Graebner
  • Publication number: 20100215707
    Abstract: Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few.
    Type: Application
    Filed: February 24, 2010
    Publication date: August 26, 2010
    Inventors: Thomas McDonald, Steven Tracy, Annika Weber
  • Patent number: 7776315
    Abstract: A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: August 17, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Michel Pairet, Michael P. Pieper, Christopher John Montague Meade, Richard Reichl, Christel Schmelzer, Birgit Jung
  • Patent number: 7766013
    Abstract: A method and device are provided to generate an aerosol having a desired particle sizes, i.e., from molecular to about 10 microns, which can be used to effectively deliver a physiologically active compound to organs and tissues such as the lung, eye, mucosa and skin. The aerosol is formed through vaporization of the compound while mixing the resulting vapor with a gas, in a ratio, to form the desired particle size when a stable concentration of particles in the gas is reached.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: August 3, 2010
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Martin J. Wensley, Daniel Mufson, Craig C. Hodges, Peter M. Lloyd, Daniel D. Rogers
  • Patent number: 7767198
    Abstract: The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: August 3, 2010
    Assignee: Novartis AG
    Inventors: Jayne E. Hastedt, Kirsten M. Cabot, David Gong, Dennis M. Hester
  • Patent number: 7758888
    Abstract: A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: July 20, 2010
    Assignee: Sol-Gel Technologies Ltd.
    Inventors: Noa Lapidot, Shlomo Magdassi, David Avnir, Claudio Rottman, Orit Gans, Alon Seri-Levy
  • Patent number: 7754242
    Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: July 13, 2010
    Assignee: Alkermes, Inc.
    Inventors: Sujit K. Basu, Giovanni Caponetti, Robert Clarke, Katharina J. Elbert
  • Patent number: 7744855
    Abstract: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: June 29, 2010
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rosella Musa
  • Patent number: 7736627
    Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: June 15, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Christel Schmelzer
  • Patent number: 7735485
    Abstract: A dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system is characterized by using a combination of: (1) a vessel housing a freeze-dried composition prepared by freeze-drying a composition liquid containing ingredients in a non-dissolved form, and has: (i) a non-powder cake-like form, (ii) a disintegration index of 0.05 or more, and (iii) a property of becoming fine particles having a mean particle diameter (mass median aerodynamic diameter) of 10 microns or less or a fine particle fraction of 10% or more upon receipt of an air impact having an air speed of at least 1 m/sec and an air flow rate of at least 17 ml/sec; and (2) a device comprising a member capable of applying the air impact to the freeze-dried composition in said vessel, and a member for discharging the powder-form freeze-dried composition that has been made into fine particles.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: June 15, 2010
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Chikamasa Yamashita, Akitsuna Akagi, Yuichiro Fukunaga
  • Patent number: 7736628
    Abstract: The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: June 15, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bernd Wilhelm Mueller, Hartwig Andreas Steckel, Inga-Lis Timmermann, Michael Trunk
  • Patent number: 7736626
    Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: June 15, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Christel Schmelzer
  • Publication number: 20100143268
    Abstract: A formulation suitable for delivery from a pressurised metered dose inhaler comprises a hydrofluoroalkane liquid, which is pharmaceutically acceptable, for instance HFA 134a or HFA 227, a drug to be delivered to the lung which is insoluble in the hydrofluoroalkane, the drug being in particulate form in the composition, further containing a suspension stabiliser which is a non-toxic essential oil miscible with the hydrofluoroalkane liquid at room temperature. The essential oil is preferably one having some amphiphilic property, such as a ketone or aldehyde compound. Insulin may be formulated for inhalation.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 10, 2010
    Inventors: Ian Walter Kellaway, Kevin Taylor, Bildad Kimani Nyambura
  • Publication number: 20100143269
    Abstract: Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate and processes for preparing the same.
    Type: Application
    Filed: December 8, 2009
    Publication date: June 10, 2010
    Inventors: Joel A. Sequeira, Stefan A. Sharpe, John L. Hart
  • Publication number: 20100124536
    Abstract: Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 ?m or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale.
    Type: Application
    Filed: January 24, 2010
    Publication date: May 20, 2010
    Applicants: Wyeth, Novartis Pharma Ag
    Inventors: Robert G. Schaub, Nicholas W. Warne, Andrew J. Dorner, Chandra A. Webb, James C. Keith, David K. Gong, Jayne E. Hastedt
  • Patent number: 7718163
    Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material (4) on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be release from the carrier particles before actuation of the inhaler. The inclusion of additive material (4) in the powder has been found to give an increased respirable fraction of the active material.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: May 18, 2010
    Assignee: Vectura Limited (01696917)
    Inventor: John Nicholas Staniforth
  • Patent number: 7713518
    Abstract: A capsule for a powder has a body which is provided with an internal chamber (21) to hold the powder and first and second openings to an exterior environment. The body is adapted to be displaced from a filling state, in which the first and second openings are placed in fluid communication with one another through the internal chamber thereby enabling an airflow to be created through the body from the second opening to the first opening which is able to entrain powder in the exterior environment into the internal chamber for filling thereof, to a sealing state in which the internal chamber is sealed from the exterior environment so as to retain the powder held therein.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: May 11, 2010
    Assignee: Glaxo Group Limited
    Inventor: Paul Kenneth Rand
  • Publication number: 20100095963
    Abstract: Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and processes for preparing the same.
    Type: Application
    Filed: December 22, 2009
    Publication date: April 22, 2010
    Inventors: Stefan A. Sharpe, Joel A. Sequeira
  • Patent number: 7695739
    Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: April 13, 2010
    Assignee: Elan Pharma International Limited
    Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
  • Patent number: 7687453
    Abstract: A mixed micellar pharmaceutical formulation includes a micellar pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanylglycine, glycerine, polyglycerin, lysine, polylysine, triolein and mixtures thereof. Each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are is less than 50 wt./wt. % of the formulation.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: March 30, 2010
    Assignee: Generex Pharmaceuticals Incorporated
    Inventor: Pankaj Modi
  • Patent number: 7678364
    Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a multivalent metal cation which is complexed with a therapeutic, prophylactic or diagnostic agent or any combination thereof having a charge capable of complexing with the cation upon association with the agent, a pharmaceutically acceptable carrier and optionally, a multivalent metal cation-containing component wherein the total amount of multivalent metal cation present in the particles is more than 1% weight/weight of the total weight of the agent (% w/w).
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: March 16, 2010
    Assignee: Alkermes, Inc.
    Inventors: David A. Edwards, Jeffrey S. Hrkach
  • Publication number: 20100055192
    Abstract: Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device.
    Type: Application
    Filed: July 9, 2009
    Publication date: March 4, 2010
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Rossella Musa, Daniela Cocconi, Silvia Catinella
  • Publication number: 20100055049
    Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
    Type: Application
    Filed: July 27, 2007
    Publication date: March 4, 2010
    Inventors: Mei-Chang Kuo, Michael A. Eldon, YiQiong Yuan
  • Publication number: 20100047292
    Abstract: A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, positioning the multi-phasic dispersion within a chamber capable of being pressurized, pressurizing the chamber with a first gas to a pressure less than the supercritical pressure of the gas, and contacting the multi-phasic dispersion with the first gas.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 25, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Mei Tsung, D. Davidson Easson, JR., Eugene Mehr, Alain L. Bourhis
  • Patent number: 7666860
    Abstract: A melt-formulated, multiparticulate, oral dosage form containing clavulanic acid and/or at least one physiologically acceptable salt thereof and at least one sucrose fatty acid ester and optionally further physiologically acceptable auxiliary substances; a process for producing such a dosage form, combination dosage forms with ?-lactam antibiotics, and the pharmaceutical use thereof, e.g., for treating bacterial infections.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: February 23, 2010
    Assignee: Gruenenthal GmbH
    Inventors: Iris Ziegler, Johannes Bartholomaeus, Dieter Schateikis
  • Patent number: 7666395
    Abstract: Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: February 23, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Richard C. Boucher, Jr.
  • Publication number: 20100028269
    Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.
    Type: Application
    Filed: August 6, 2009
    Publication date: February 4, 2010
    Inventors: Rudi Mueller-Walz, Roland Steiner
  • Publication number: 20100015217
    Abstract: The present invention provides methods for enhancing pulmonary host defense in a subject by administering via inhalation an effective amount of granulocyte-macrophage colony stimulating factor or a functional homologue thereof. Methods of the present invention are useful in alleviating symptoms and/or treating pulmonary diseases or conditions including, but not limited to lung cancer, pneumocystis carinii, pneumonia with or without bacterial, fungal and/or viral infection including but not limited to community acquired pneumonia, nosocomial pneumonia or ventilator associated pneumonia, and or cystic fibrosis with or without bacterial, fungal and/or viral infection or colonization, bronchitis, Bronchiectasis, Diffuse panbronchiolitis, Bronchiolitis, Bronchiolitis obliterans, Bronchiolitis obliterans organizing pneumonia (BOOP) and/or bacterial, fungal and/or viral colonization or infection.
    Type: Application
    Filed: November 2, 2007
    Publication date: January 21, 2010
    Inventor: Kaare Fiala
  • Patent number: 7648960
    Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal of one or more impurities from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: January 19, 2010
    Assignee: MannKind Corporation
    Inventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
  • Patent number: 7645442
    Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300° C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: January 12, 2010
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Ron L. Hale, Peter M. Lloyd, Amy Lu, Daniel J. Myers, Reynaldo J. Quintana, Joshua D. Rabinowitz, Dennis W. Solas, Soonho Song, Curtis Tom, Martin J. Wensley
  • Publication number: 20090324512
    Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 31, 2009
    Applicant: Ablynx N.V.
    Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
  • Patent number: 7638138
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: December 29, 2009
    Assignee: Translational Research, Ltd.
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Patent number: 7628977
    Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: December 8, 2009
    Assignees: Massachusetts Institute of Technology, The Penn State Research Foundation
    Inventors: David A. Edwards, Robert S. Langer, Rita Vanbever, Jeffrey Mintzes, Jue Wang, Donghao Chen